Runxin bio-class 1 new drug completed phase 2 clinical first patients.

Runxin Bio announced that its phase 2 clinical study on the treatment of relapsed metastatic head and neck squamous cancer with the new drug RX108 recently completed the first patient administration at Shanghai Oriental Hospital.
RX108 is a kind of innovative drug with global intellectual property rights developed by Runxin Bio, is a novel Na/K-ATP enzyme inhibitor, has a "one-target multi-point" mechanism, can play an anti-tumor role through a variety of ways.
currently conducting several clinical studies on different solid tumors in China and the United States.
The first clinical study to be completed was a single-arm, open, multi-center Phase 2 clinical trial designed to evaluate the safety and effectiveness of RX108 in patients with relapsed metastatic head and neck squamous cancer who had failed platinum-containing treatments in the past.
head and neck squamous cancer is one of the most common malignancies, accounting for 6% of all tumors, the world's annual increase of about 750,000 cases.
more than 60% of patients with head and neck squamous cancer are locally advanced or metastatic at the time of diagnosis. "For relapsed metastatic head and neck squamous cancer, although great breakthroughs have been made in immunotherapy in recent years, there is still a great unsophisticated demand for new targeted drugs to improve the overall prognostication," said Professor Guo Wei of Shanghai Oriental Hospital, chairman of the
CSCO Head and Neck Cancer Professional Committee.
" study is the first Phase 2 clinical study of RX108 in China, an important milestone in the RX108 clinical development process.
hope that RX108 will provide new treatment options for patients with relapsed metastatic head and neck squamous cancer.
.